Targeted probiotic therapy in irritable bowel syndrome: a clinical evaluation on Clostridium butyricum CBM588 and Bifidobacterium longum W11
This study supports the use of <i>C. butyricum</i> CBM588 and <i>B. longum</i> W11 as effective probiotic interventions for IBS-D and IBS-C, respectively. Their strain-specific benefits highlight the potential of targeted probiotic strategies in IBS management. Future studies with larger sample sizes and longer follow-up periods are recommended to confirm and expand these findings.
Authors
- Nadia Lazzerini
- Chiara Maria Palazzi (ORCID: https://orcid.org/0009-0006-8807-3029)
- Giordano Bruno Zonzini
- Davide Sisti (ORCID: https://orcid.org/0000-0002-7925-7495)
- Alexander Bertuccioli (ORCID: https://orcid.org/0000-0002-3922-9115)
- Mirko Ragazzini (ORCID: https://orcid.org/0000-0002-7130-5157)
- Annalisa Belli
Institutions
- University of Urbino (IT)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-05-20
- DOI
- https://doi.org/10.3389/fmed.2025.1604319
- Citations
- 3
- Primary Topic
- Gastrointestinal motility and disorders
- Type
- article
- Field-Weighted Citation Impact
- 5.43